- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05182528
Hematological Disorders in Covid 19 Patients
Study Overview
Status
Conditions
Detailed Description
Covid 19 is an infectious disease caused by a newly discovered coronavirus.most people infected with the covid 19 virus will have mild to moderate respiratory illness and recover without specific treatment.older people and those with underlying medical problems like cardiac diseases,diabetes,any chronic respiratory disease and cancer are more likely to have serious illness.the covid 19 virus spreads primarily through droplets of saliva or discharge from the nose oral cavity when an infected person coughs or sneezes.people with covid19 have had a wide range of symptoms reported _ranging from mild to severe symptoms.symptoms may appear 2_14 days after exposure to the infection .any one can have mild to severe symptoms.people with these symptoms may have covid 19: fever or shivering,cough,shortness of breath,fatigue,body or muscle aches,headache,new loss of smell or taste ,sore thraot,congestion or running nose , nausea or vomiting,diarrhoea.
The most common hematological clinical findings include lymphocytopenia,neutrophilia,eosinophilia,mild thrombocytopenia,and less frequently thrombocytosis,the presence of reactive lymphocytes has been reported only occasionally the leucocyte count may be normal,reduced or increased.according to a meta analysis leucocytosis,lymphopenia and thrombocytopenia are associated with greater severity and fatality in covid 19 cases
Study Type
Enrollment (Anticipated)
Contacts and Locations
Study Contact
- Name: Radwa mahmoud
- Phone Number: 01001673731
- Email: Radwaamahmoud11@gmail.com
Study Contact Backup
- Name: mohamed hossam maghraby
- Phone Number: 01002621166
- Email: Mohamedmaghraby@yahoo.com
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
all covid 19 patients diagnosed by pcr or CT chest
-
Exclusion Criteria:
- No
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Hematological disorders in covid 19 patients
Time Frame: Baseline
|
to detect hematological abnormalities in covid 19 patients and its correlation to outcome and severity of the disease
|
Baseline
|
Collaborators and Investigators
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Anticipated)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- Hematological disorders
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hematological Abnormalities in covid19
-
Groupe Hospitalier Pitie-SalpetriereInstitut National de la Santé Et de la Recherche Médicale, FranceCompletedHematological Abnormality | HematotoxicityFrance
-
Assiut UniversityCompletedHematological Condition With COVID19Egypt
-
Gruppo Italiano Malattie EMatologiche dell'AdultoCompletedCovid19 | Hematological MalignancyItaly
-
Alla KeyznerCompletedMyelodysplastic Syndromes | Hodgkin Lymphoma | Non-Hodgkin Lymphoma | Acute Leukemia in Remission | Hematological Malignancy | Acute Lymphoblastic Leukemia in RemissionUnited States
-
Sorveglianza Epidemiologica Infezioni Fungine Emopatie...European Hematology AssociationRecruitingCOVID-19 Infection in Hematological Malignancies PatientsItaly
-
Labplus Sp. z o.o.CompletedAbnormalities in the Blood Test ResultsPoland
-
University of Milano BicoccaCompletedCovid19 | Thalassemia MajorItaly
-
Mindchild Medical Inc.Completed
-
Saint Luke's Health SystemTerminatedCongenital Heart Disease in Pregnancy | Heart Diseases in PregnancyUnited States
-
UMC UtrechtMaastricht University Medical Center; Erasmus Medical Center; Academisch Medisch... and other collaboratorsCompletedIntrauterine Abnormalities in InfertilityNetherlands